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DObjective: Because of its durability, the mechanical valve is typically chosen for young patients undergoing
mitral valve replacement (MVR). However, a bioprosthetic valve might have the benefit of valve-in-valve trans-
catheter valve replacement whenvalve failure occurs.We examined the outcomes in patients who had undergone
mechanical valve MVR (MVRm) versus bioprosthetic valve MVR (MVRb) in patients aged<65 years.
Methods: A total of 768 consecutive patients aged<65 years, who had undergone MVR from January 1991 to
June 2012 were identified. Propensity matching was used to derive a case-control subset for analysis. Long-term
outcomes were collected by chart review, routine patient follow-up, and query of the Social Security Death
Index. The postoperative and long-term outcomes of interest included combined stroke and embolic events,
reoperations, and mortality.
Results: Of 768 consecutive patients, 627 were in the MVRm and 141 in the MVRb group. Propensity score
matching yielded a cohort of 125 MVRb (89%) and 125 control MVRm patients with similar etiology mixes.
The groups were similar in age (MVRm, 53.2  9.0 years; MVRb, 53.8  10.6 years; P ¼ .617) and other
preoperative characteristics. The postoperative outcomes were also similar between the 2 groups, including
reoperation for bleeding, stroke, deep sternal infection, sepsis, and length of hospital stay. The operative
mortality was also similar (MVRm, 5.6%; MVRb, 8.0%; P ¼ .617). However, Kaplan-Meier analysis showed
the MVRb group had a greater reoperation rate (P ¼ .001) and shorter estimated survival (11.3 vs 13.5 years,
P ¼ .004). The incidence of bleeding and stroke or embolic events between the 2 groups was similar.
Conclusions: In the present report, MVRb for patients<65 years old was associated with a high reoperation rate
and decreased survival. Although a future transcatheter valve-in-valve technique for a failed bioprosthetic
valve might reduce the risk of reoperation, this finding confirms the safety of mechanical valves in this group.
(J Thorac Cardiovasc Surg 2014;147:117-26)The momentum toward the use of bioprosthetic valves for
mitral valve replacement (MVR) has been great. From the
Society of Thoracic Surgeons database, usage of the
mechanical valve has decreased from 68% in 2000 to
37% in 2007.1 The median age of the patients receiving
bioprosthetic valves has decreased significantly from 77
in 2000 to 71 in 2007, and this trend is likely to continue.
Classic teaching has recommended mechanical valves for
younger patients to avoid structural valve deterioration
(SVD) at the expense of lifetime anticoagulation. However,
the lower SVD rate with current bioprostheses, the lower
risk of reoperation, and young patients’ decision to note Department of Cardiac Surgery, Brigham and Women’s Hospital, Boston,
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lants have all contributed to the recent lower age cutoff
for the use of bioprostheses.2
ForMVR, the American College of Cardiology/American
Heart Association guideline from 2008 has provided no
age criteria for the class I recommendation. The class IIa
recommendations are to use the mechanical valve in patients
aged<65 years with atrial fibrillation. The bioprosthetic
valve has been recommended for patients aged<65 years
who are in sinus rhythm and who have elected to receive
this valve for lifestyle considerations after detailed
discussions of the risks of anticoagulation versus the
likelihood that a second MVR might be necessary in
the future.3 The European Society of Cardiology and the
European Association for Cardio-Thoracic Surgery guide-
line has recommended the mechanical valve for those aged
<65 years for MVR.4
Two randomized control studies were conducted in the
1970s to assess the outcomes between mechanical and
bioprosthetic valves in the mitral position. Neither study
showed any difference in survival.5,6 However, these
studies did not focus on any specific age group. Few data
exist on the specific group<65 years old when comparing
the outcomes of mechanical versus bioprosthetic valves inrdiovascular Surgery c Volume 147, Number 1 117
Abbreviations and Acronyms
EMRs ¼ electronic medical records
MVR ¼ mitral valve replacement
SVD ¼ structural valve deterioration
TMVR ¼ transcatheter mitral valve replacement
VIV ¼ valve-in-valve
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DMVR. With the recent enthusiasm of valve-in-valve
(VIV) transcatheter MVR (TMVR), the trend of patients
receiving a bioprosthetic valve at a younger age will
likely accelerate. Therefore, it is critical to understand the
outcomes of receiving a mechanical versus bioprosthetic
valve for MVR at a younger age.
The aim of the present study was to review the immediate
and long-term outcomes of mechanical versus bioprosthetic
MVR in patients <65 years old to provide information
regarding valve selection in this age group.METHODS
Patient Selection
A retrospective review of the hospital electronic medical records
(EMRs) was conducted to identify all MVRs performed with a mechanical
(MVRm) or stented bioprosthetic (MVRb) valve from January 1991 to
June 2012 in patients aged<65 years old. Patients who had undergone
multiple surgeries were included in the present study if they were<65
years old. A total of 768 patients underwent MVR within the study period.
Patients who had undergone any type of previous cardiac surgery were
included in the cohort. The exclusion criteria included any MVR
performed in patients>65 years; no exclusions were made on gender,
race, or other concomitant cardiac surgery. Our internal review board
approved the present study.
Data Collection
The patient characteristics, medications, laboratory values, and in-
hospital outcomes of the index surgery were collected at presentation
and extracted from the patients’ EMRs. Mortality data, including the cause
of death, were collected from the following sources: the Social Security
Death Index, EMRs, and the Registry of Vital Records and Statistics,
Department of Public Health (Dorchester, Mass). The long-term outcomes
were extracted from a chart review of the EMRs, our internal outcomes
data repository, and routine patient follow-up findings. We had 100%
follow-up at 30 days and 99.1% long-term follow-up using our various
sources.
The patient demographics and hospital outcomes were coded and
defined according to the Society for Thoracic Surgeons Adult Cardiac
Surgery database specifications, version 2.52. Our primary short-term
outcomes of interest were 30-day mortality, postoperative stroke, and
re-exploration for bleeding. The secondary outcomes of in-hospital cardiac
arrest, complete heart block, duration of ventilator use, intensive care unit
length of stay, and hospital length of stay were also assessed. The long-term
outcomes of interest were mortality, strokes and embolic events, major
bleeding events, and valve-related reoperations. Major bleeding events
were defined as presentations to a clinical office or emergency room for
bleeding, bleeding that required medical intervention, and any unexpected
or excessive bleeding as a complication of a procedure or other clinical
intervention. The interval to a long-term event was calculated in months
from the date of surgery to the first documented qualifying event, or if
none occurred, to March 31, 2013.118 The Journal of Thoracic and Cardiovascular SurgStatistical Analysis
Normally distributed continuous variables are presented as the
mean standard deviation. Non-normally distributed continuous variables
are presented as the median and interquartile range. Analyses of continuous
variables were done using Student’s t test with Levine’s homogeneity of
variance or the Mann-Whitney U test, as appropriate. Dichotomous
variables were evaluated using Fisher’s exact test and are presented as
numbers and percentages. Survival and the interval to outcomes of interest
were analyzed using the Kaplan-Meier method and life table estimations.
Multivariate analysis of long-term survival was done using a forward
stepwise Cox regression. For this analysis, we selected variables according
to their clinical significance, variability across study cohorts, and known
contributions to life expectancy. Interaction terms were examined. All
statistical analyses were done using the Statistical Package for Social
Sciences, version 13.0 (SPSS, Chicago, Ill) with P  .05 as the criterion
for significance.
Propensity Matching
We conducted a matched group analysis using propensity matched
cases of MVRb and MVRm. Propensity scores were generated using
logistic regression analyses in 2 steps. Potential predictors were selected
from a published data review, known confounding covariates for
the outcomes of interest, differences between the 2 patient groups
(Table 1), and clinical judgment. A forward-stepwise regression
analysis was conducted, including examinations for interaction effects.
An interaction variable between the surgeon and year of surgery was
also examined to control for variability in case mix and surgical practice
over time. Any variable with P  .15 was entered into an enter-method
logistic regression analysis. The resulting adjusted predicted probability
for each patient was then used to select matched groups according to
probability scores of <.01 (a priori algorithm). This final model was
moderately robust (area under the curve, 0.734; 95% confidence
interval, 0.686-0.782; P<.001) and contained age (in years), history of
hypercholesterolemia, hypertension, renal failure, active endocarditis,
ischemic disease, operative status (elective, urgent, or emergent)
perfusion time (in minutes), and year of surgery. The resultant score
was used to match the MVRm controls to MVRb cases with an equal
or nearest probability score (within 0.01). Overall, 125 MVRb cases
were matched 1:1 to 125 MVRm controls (88.7%).
RESULTS
Total Cohort
Of 768 consecutive patients, 627 had undergone MVRm
and 141 MVRb. The median follow-up period was 7 years
(8 years for MVRm and 3 years for MVRb), for a total of
5899 patient-years during the study period. The characteris-
tics and in-hospital outcomes are listed in Table 1.
The patients in the MVRb group were older (54.3 10.3
years vs 51.8 9.7 years, P¼ .005) and were more likely to
have a history of renal failure (25 of 414 vs 62 of 627,
P¼ .012). The remaining characteristics were substantially
similar regarding the proportion of women, left ventricular
ejection fraction, New York Heart Association class, and
cardiac surgery history.
Both groups had similar cardiac history. Of the MVRm
and MVRb groups, 6.4% (40 of 627) and 8.5% (12 of
141) had undergone previous coronary artery bypass
grafting (CABG, P ¼ .356), 18.8% (118 of 627) and
18.4% (26 of 141) had undergone previous valve surgery
(P ¼ 1.000), and 1.8% (11 of 627) and 5.0% (7 of 141)ery c January 2014
TABLE 1. Characteristics and in-hospital outcomes for whole cohort
Variable
MVRm
(n ¼ 627)
MVRb
(n ¼ 141)
P
value
Preoperative data
Age (y) 51.8  9.7 54.3  10.3 .005
Female gender 57.3 (359) 55.3 (78) .707
Renal failure 9.9 (62) 17.7 (25) .012
Preoperative creatinine
(mg/dL)
1.31  1.5 1.34  1.1 .799
Ejection fraction (%) 60 (50-65) 60 (50-65) .767
NYHA class III-IV 54.1 (339) 52.5 (74) .779
Previous CABG 6.4 (40) 8.5 (12) .356
Previous valve surgery 18.8 (118) 18.4 (26) 1.000
Previous CABG and valve
surgery
1.8 (11) 5.0 (7) .320
Etiology
Active endocarditis 8.5 (53) 14.2 (20) .055
Healed endocarditis 3.0 (19) 2.1 (3) .781
Rheumatic 40.2 (252) 31.2 (44) .055
Myxomatous 15.8 (99) 12.8 (18) .437
Ischemic 7.3 (46) 14.2 (20) .012
Nonischemic
cardiomyopathy
1.9 (12) 0.7 (1) .481
Other 23.3 (146) 24.8 (35) .742
Operative data
Minimally invasive 5.9 (37) 2.8 (4) .211
Concomitant CABG 18.3 (115) 22.0 (31) .342
Perfusion time (min) 158 (116-217) 169 (121-217) .158
Crossclamp time (min) 109 (75-158) 117 (87-163) .050
Postoperative outcomes
Reoperation for bleeding 4.6 (29) 5.0 (7) .827
Redo valve 0.5 (3) 0.0 (0) 1.000
Permanent stroke 2.2 (14) 5.7 (8) .044
DSWI 0.6 (4) 2.1 (3) .120
Sepsis 1.1 (7) 3.5 (5) .051
MSOF 0.6 (4) 2.8 (4) .042
LOS (d) 8 (6-13) 9 (6-17) .205
Operative mortality 4.5 (28) 8.5 (12) .059
Estimated survival (y) 16.2 10.6 .001
Data presented as mean standard deviation,% (n), or median (interquartile range).
MVRm, Mitral valve replacement with mechanical valve; MVRb, MVR with
bioprosthetic valve; NYHA, New York Heart Association; CABG, coronary artery
bypass grafting; DSWI, deep sternal wound infection; MSOF, multisystem organ
failure; LOS, length of stay.
TABLE 2. Implanted bioprosthetic valve type
Bioprosthetic valve type n (%)
Biocor 28 (19.9)
Carpentier Edwards Pericardial 50 (35.5)
Carpentier Edwards Porcine 6 (4.3)
Epic 9 (6.1)
Hancock 24 (17.0)
Hancock II 3 (2.1)
Magna Ease 10 (7.1)
Mosaic Porcine 11 (7.8)
Total 141 (100)
Biocor and Epic, St Jude Medical, St Paul, Minn; Carpentier Edwards Pericardial and
Porcine, Magna Ease, Edwards Lifesciences, Irvine, Calif; Hancock, Hancock II, and
Mosaic Porcine, Medtronics, Minneapolis, Minn.
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simultaneously, respectively.
The indications for surgery were different between the 2
groups. The MVRb patients were more likely to have active
endocarditis (MVRb vs MVRm, 20 of 141 vs 53 of 627,
respectively; P ¼ .055) or an ischemic etiology (MVRb
vs MVRm, 20 of 141 vs 46 of 627, respectively;
P ¼ .012) as an indication for surgery. In contrast,
rheumatic disease was more frequent in the MVRm group
than in the MVRb group (252 of 627 vs 44 of 141,
P ¼ .055).
The operative data showed a longer crossclamp time for
MVRb (109 vs 117minutes, P¼ .05) but a similar perfusionThe Journal of Thoracic and Catime (158 vs 169 minutes, P ¼ .158). Of the MVRm and
MVRb patients, 18.3% (115 of 627) and 22.0% (31 of
141) patients had undergone concomitant CABG at surgery
(P ¼ .342). The type of bioprosthetic valves implanted is
listed in Table 2. The most commonly used valve was the
Carpentier Edwards Pericardial valve (Edwards Lifescien-
ces, Irvine, Calif) in 50 patients (35.5%) followed by the
Biocor valve (St JudeMedical, St Paul, Minn) in 28 patients
(19.9%). Hancock I valves (Medtronics, Minneapolis,
Minn) were used from 1992 to 2000 and were implanted
in 24 patients (17.0%).
Postoperatively, the MVRb group experienced signifi-
cantly more strokes (8 of 141 vs 14 of 627, P ¼ .044) and
a greater incidence of sepsis (5 of 141 vs 7 of 627,
P ¼ .044) and multisystem organ failure (4 of 141 vs 4 of
627, P ¼ .042). Operative mortality was also greater in
the MVRb group (8.5%, 12 of 141 MVRb vs 4.5%, 28 of
627 MVRm, P ¼ .059). The estimated postoperative
survival was shorter in the MVRb than in the MVRm group
(median, 10.6 years vs 16.2 years, respectively; P<.001).
Wewere able to identify the long-termmedication list for
132 of the 141 patients (93.6%) in the MVRb group. We
found that 34 of the 132 patients (25.8%) were taking
warfarin in the long term. Postoperative new-onset atrial
fibrillation was seen in 15.8% of the MVRm and 18.4%
of the MVRb groups.
Propensity Matched Analysis
Because of the inherent differences between the patient
populations, we sought to create a case-control analysis
using propensity matched cases. The characteristics and
outcomes for the 125MVRb cases and 125MVRm controls
are listed in Table 3. Statistically significant differences in
the whole group, such as age, preoperative renal failure,
endocarditis, and crossclamp time, were all matched.
Overall, these groups were substantially similar in age,
preoperative medical history, disease etiology, cardiac
history, and operative outcomes.
After correction for these characteristics, the inci-
dence of previously different in-hospital postoperativerdiovascular Surgery c Volume 147, Number 1 119
TABLE 3. Characteristics and in-hospital outcomes for 250 matched
patients
Variable
MVRm
(n ¼ 125)
MVRb
(n ¼ 125)
P
value
Preoperative data
Age (y) 53.2  9.0 53.8  10.6 .617
Female gender 60.8 (49) 53.6 (43) .307
Renal failure 20.0 (16) 16.0 (13) .511
Preoperative creatinine
(mg/dL)
1.36  1.2 1.34  1.2 .888
Ejection fraction (%) 60 (50-65) 60 (50-65) .767
NYHA class III-IV 55.2 (44) 51.2 (41) .612
Previous CABG 3.2 (4) 4.9 (5) 1.000
Previous valve surgery 24.0 (30) 13.6 (17) .520
Previous CABG and valve
surgery
2.4 (3) 4.0 (5) .722
Etiology
Endocarditis 12.8 (10) 12.8 (10) 1.000
Ischemic 12.0 (10) 12.8 (10) 1.000
Operative data
Concomitant CABG 18.4 (15) 23.2 (19) .342
Perfusion time (min) 162 (113-220) 170 (121-215) .691
Crossclamp time (min) 112 (79-161) 114 (86-161) .733
Postoperative outcomes
Reoperation for bleeding 4.8 (4) 5.6 (4) 1.000
Redo valve 0.0 (0) 0.0 (0)
Permanent stroke 2.4 (2) 6.4 (5) .216
DSWI 0.8 (1) 2.4 (2) .622
Sepsis 2.4 (2) 1.6 (1) 1.000
MSOF 0.8 (1) 2.4 (2) .622
LOS (d) 9 (7-14) 9 (6-16) .817
Operative mortality 5.6 (4) 8.0 (6) .617
Estimated survival (y) 13.5 (0.7) 11.3 (1.0) .004
Data presented as mean standard deviation,% (n), or median (interquartile range).
MVRm, Mitral valve replacement with mechanical valve; MVRb, MVR with
bioprosthetic valve; NYHA, New York Heart Association; CABG, coronary artery
bypass grafting; DSWI, deep sternal wound infection; MSOF, multisystem organ
failure; LOS, length of stay.
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Dcomplications, including stroke, sepsis, deep sternal
infection, and multisystem organ failure, was similar
between the 2 groups. Operative mortality was similar after
correction (5.6%, MVRm and 8.0%, MVRb; P ¼ .617).
However, the long-term survival differences persisted,
with an estimated median survival of 11.3 years for
MVRb patients and 13.7 years for MVRm patients
(P ¼ .004).
Long-Term Outcomes
Stroke or embolic event. Figure 1 shows the Kaplan-
Meier analysis of the long-term risk of stroke or an embolic
event. A total of 46 stroke or embolic events occurred. Of
these, 40 were in the MVRm group and 6 in the MVRb
group. The estimated freedom from stroke and embolic
events at 5, 10, and 15 years was 95.3%, 93.2%, and
90.7% for the MVRm group and 93.7%, 87.6%, and
87.6% for the MVRb group, respectively. No differences120 The Journal of Thoracic and Cardiovascular Surgwere seen between the MVRm and MVRb patients after a
follow-up period of 240 months (P ¼ .912).
Bleeding events. Figure 2 shows the Kaplan-Meier estima-
tion of reported bleeding events. The estimated freedom
from major bleeding at 5, 10, and 15 years was 87.2%,
79.2%, and 71.2% for the MVRm group and 91.1%,
85.0%, and 77.9% for the MVRb group, respectively.
Although a greater cumulative proportion of MVRm
patients experienced a bleeding event, the difference was
not statistically significant (P ¼ .196).
Reoperations. Figure 3 shows the Kaplan-Meier curves
for valve-related reoperations. The freedom from reopera-
tion was estimated at 97.7%, 96.6%, and 96.1% for the
MVRm group and 96.6%, 86.6%, and 75.3% for the
MVRb group at 5, 10, and 15 years, respectively. The risk
of reoperation was significantly greater for the MVRb
patients (P ¼ .003).
Long-term survival. Figure 4 shows the long-term
survival in the total and matched cohorts. The estimated
5-, 10-, and 15-year survival was 82.1%, 68.5%, and
54.1% for the MVRm patients and 65.8%, 55.0%, and
38.5% for the MVR patients, respectively (P < .001).
Even when the patient characteristics were controlled for
in the propensity matched group, the survival differences
persisted, with an estimated 5-, 10-, and 15-year survival
of 83.4%, 69.2%, and 62.6% in the MVRm group and
67.3%, 57.6%, and 40.4% in the MVRb group (P¼ .004).
Cox regression analysis. We conducted a Cox regression
analysis to evaluate the predictors of long-term survival
using the total study cohort (Table 4). Increasing age
(P  .001), perfusion time (P  .001), and elevated
creatinine (P .001) all increased the risk of mortality. Pre-
vious CABG or valve surgery (P ¼ .017 and P ¼ .026,
respectively), urgent or emergent surgical status (vs elec-
tive, P ¼ .006), and a history of congestive heart failure
(P¼ .002) or hypercholesterolemia (P¼ .05) also increased
the risk of mortality. When controlling for such factors,
our multivariate analysis revealed that mortality was
elevated for the MVRb cohort compared with the MVRm
cohort (hazard ratio, 1.476; 95% confidence interval,
1.073-2.031, P ¼ .017). Other variables tested, such as
preoperative low ejection fraction, endocarditis, female
gender, New York Heart Association class III and IV, a
history of cerebrovascular accident, high body mass index,
ischemic etiology, body surface area, and hypertension,
were not associated with mortality (P>.05).
DISCUSSION
In patients>65 years old, the use of bioprosthetic valves
for MVR has been supported by the low rate of SVD
and hemorrhagic complications.7,8 However, for patients
<65 years old, bioprosthetic valves have experienced
earlier calcification, leading to reoperation and limited
durability.9 The decision of valve choice must be made byery c January 2014
FIGURE 1. Kaplan-Meier curve of strokeand embolic events.MVRm,Mitral valve replacementwithmechanical valve;MVRb,MVRwith bioprosthetic valve.
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required with mechanical valves and the patient’s lifestyle
in younger patients.FIGURE 2. Kaplan-Meier curve of bleeding events. MVRm, Mitral valve rep
The Journal of Thoracic and CaThe question ‘‘which valve has a better outcome in
patients <65 years who are undergoing MVR’’ remains
controversial. Only 2 randomized control studies regardinglacement with mechanical valve; MVRb, MVR with bioprosthetic valve.
rdiovascular Surgery c Volume 147, Number 1 121
FIGURE 3. Kaplan-Meier curve of reoperation of mitral valve.MVRm, Mitral valve replacement with mechanical valve;MVRb, MVR with bioprosthetic
valve.
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position have been conducted. The Edinburgh study5 and
the Veterans Affairs study6 from the 1970s showed similar
survival after 20 and 15 years of follow-up, respectively.
Both showed a greater incidence of bleeding complications
with mechanical valves and a greater reoperation rate with
bioprosthetic valves. Although the findings from these
studies are important, they examined older generation
prostheses, and no outcome was reported for a specific
age group.
The present study was the 1 of the largest retrospective
studies to date on this subject. The main finding of our study
was that MVRb group <65 years old had an increased
reoperation rate and shorter long-term survival, even after
the propensity matched analysis. The incidence of bleeding
and stroke and embolic events was similar between the
2 groups. These finding are different from the 2 previous
randomized control studies and recent retrospective studies
that reported similar survival between those receiving
mechanical and biologic prostheses.10,11
Survival
The reported 10-year survival after MVR for those
<65 years has been 65% to 78% with bioprosthetic
and 60% to 76% with mechanical valves in recent
studies.10-12 Our 10-year survival in the present study was
at the lower end of survival compared with the previously122 The Journal of Thoracic and Cardiovascular Surgreported mortality. The operative mortality was greater in
the MVRb group before propensity matching, but this
difference disappeared after cohort matching. Our operative
mortality of 5.6% in the MVRm group and 8.0% in the
MVRb group was lower than the reported result of 10%
to 12.5%.12,13 The lower long-term survival in conjunction
with the low operative mortality can be explained by our
high-risk patient population. Our first choice for mitral
valve regurgitation has been mitral valve repair. A high
threshold for repair leaves high-risk candidates undergoing
replacement. Also, 18.3% of the MVRm group and 22.0%
of the MVRb group underwent concomitant CABG and
18.8% and 18.3% had undergone previous valve surgery,
respectively. The survival benefit of the mechanical
valve persisted after propensity matching. As mentioned,
previous studies had reported similar mid- and long-term
survival between mechanical and bioprostheses. We have
discussed some of the variables that might have affected
the outcomes in our study.
Reoperation
The reoperation rate was significantly greater in the
MVRb group. SVD is a known Achilles heel of
bioprosthetic valve that leads to reoperation. This is
especially true in young patients. Ruel and associates10
published their data from 214 patients who had undergone
MVR before the age of 60 years. The median interval toery c January 2014
FIGURE 4. A, Kaplan-Meier curve of survival for all 761 patients. B, Kaplan-Meier curve of survival for 250-patient matched cohort.MVRm, Mitral valve
replacement with mechanical valve; MVRb, MVR with bioprosthetic valve.
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TABLE 4. Cox regression analysis* for significant predictors of
long-term mortality
Variable P value HR 95% CI
Age .001 1.055 1.038-1.072
Perfusion time .001 1.005 1.004-1.006
Preoperative creatinine .001 1.351 1.275-1.431
Congestive heart failure .002 0.643 0.487-0.847
Urgent or emergent surgery .006 1.448 1.112-1.885
Previous CABG .017 1.587 1.088-2.316
Biologic valve .017 1.476 1.073-2.031
Previous valve surgery .026 1.439 1.045-1.982
Hypercholesterolemia .050 1.299 1.000-1.687
Nonsignificant variables tested
Preoperative ejection fraction .075
Endocarditis .227
Female gender .334
NYHA class .391
History of cerebrovascular accident .523
Body mass index .617
Ischemic etiology .784
Body surface area .910
Hypertension .949
Model performance: 2 log likelihood, 2945.533; chi-square, 285.699; degree of
freedom, 7; P  .001. HR, Hazard ratio; CI, confidence interval; CABG, coronary
artery bypass grafting; NYHA, New York Heart Association.
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24.4 years with the mechanical prostheses. Jamieson and
associates8 reported an actual freedom from valve-related
reoperation at 15 years for bioprosthetic valves of<50%
in patients<60 years and improved valve-related mortality
in the mechanical group, except in those>70 years old. Our
findings have confirmed these data, with bioprosthetic
valves in the younger population associated with a greater
risk of reoperation.
The valve type is considered an important risk factor for
reoperation. The actual freedom from SVD has been
reported to be 92% in those aged>70 years, 70% in those
aged 61 to 70 years, and 56% in those aged<60 years at
15 years with the Carpentier-Edwards supra-annular
(Edwards Lifesciences) porcine bioprosthesis.13 This is
much lower than that for the new-generation valves such
as the St Jude Medical Biocor valve (St Jude Medical),14
with actual freedom from SVD of 89% in those aged 61
to 70 years and 79% in those aged 51 to 60 years at 17
years. However, we examined our bioprosthetic valve
type and found that the valve type was not related to an
increased reoperation rate, even in the older generation
valves.
Repeat replacement of the mitral valve is not without
risk. Recent data have still reported mortality for repeat
replacement of the mitral valve of 5% to 7%, although
this has decreased compared with previous reports.15-17
Hence, reoperation will likely affect the long-term survival
of patients who require intervention.124 The Journal of Thoracic and Cardiovascular SurgBleeding
Bleeding is considered a major problem for mechanical
valves, because the mechanical valve requires lifelong anti-
coagulation. Previous randomized control studies5,6 and a
recent retrospective study11 showed a greater bleeding
rate with the mechanical valve. However, Badhwar and
associates18 reported no difference in the bleeding rate
between mechanical and bioprosthetic valves in their
propensity matched analysis for patients<65 years who
had undergone valve replacement (both aortic valve
replacement and MVR included). They used a lower inter-
national normalized ratio goal (2.5 in the MVR group) and
frequent international normalized ratio point-of-care
checks at home, which might have decreased the incidence
of bleeding. Excellent international normalized ratio man-
agement within their healthcare system and by caregivers
could be 1 of possible explanations for the similar bleeding
rate in the mechanical valve patients. Stassano and associ-
ates19 performed a randomized control study of patients
aged 55 to 70 years who were undergoing aortic valve
replacement. In that study, the mechanical valve resulted
in a bleeding risk similar to that of the bioprosthetic valve.19
An increased number of patients in the bioprosthetic group
required anticoagulation, especially with the longer follow-
up period, for causes such as atrial fibrillation, transient
ischemic attack, and chamber enlargement, although the
exact number was not reported.19 Our follow-up showed
that 25.8% of patients who received bioprosthetic valves
required warfarin in the long term. This was likely because
18.4% of the patients who had received bioprosthetic
valves had developed new-onset atrial fibrillation and might
explain why the bioprosthetic group had a bleeding risk
similar to that of the mechanical group.
The similar bleeding risks might explain why the survival
was longer inmechanical group.The riskofvalve implantation
at a younger age is mainly bleeding with the mechanical valve
and reoperation with the bioprosthetic valve.20 If the bleeding
risk was similar between the 2 valve types, the bioprosthetic
valve would have a greater risk because of reoperation.
Thromboembolic Events
Thromboembolic events occurred less frequently and
resulted in fewer deaths in patients<65 years old.21 Also,
other risk factors, such as coronary artery disease, atrial
fibrillation, and poor left ventricular function, are less
common in younger patients. Recent retrospective studies
have shown a similar incidence of thromboembolic events
between mechanical and bioprosthetic valves.10,11 The
present study has confirmed that no increase occurred in
thromboembolic events with the mechanical valves.
Predictors of Long-Term Mortality
In our Cox regression analysis, we identified multiple
significant predictors of long-term mortality. Increasedery c January 2014
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Dage, a long perfusion time, preoperative high creatinine, a
history of congestive heart failure, urgent or emergent
surgery, previous CABG and/or valve surgery, hyper-
cholesterolemia, and biologic valve implantation were all
statistically significant risk factors for patients undergoing
MVR. The published data support our findings. Age at
operation, coronary artery disease, class IV heart failure,
reoperation, and renal disease were all reported risk factors
for MVR for those aged<60 years.10,12 However, valve
type was not reported to be a risk factor, differing from
our results.
Future Considerations for Transcatheter Procedures
A previously placed bioprosthetic valve will allow VIV
TMVR using the strut at reoperation. This technique has
been welcomed with high expectations and has become 1
of the greatest reasons for receiving a bioprosthetic valve
at a younger age. The consensus has been that patients
will be able to receive a minimally invasive procedure
without sternotomy and cardiopulmonary bypass when
reoperation is required. However, only small case series
have been reported regarding VIV TMVR to support this
consensus. The largest series to date was presented by
Dvir and associates at PCR London Valves 2012. From
the global VIV registry, 91 patients who had undergone
VIV TMVR were included in that study. They reported a
30-day mortality of 11.9% and 1-year survival of 74.5%.
Although the future of this technique seems promising,
the long-term outcomes and valve durability are still
unknown, and larger series with longer follow-up are
needed. The use of the VIV technique as a reason for
implanting bioprosthetic valves in younger patients needs
to be used with caution, especially with the shorter survival
with bioprosthetic valves shown in the present study.
Study Limitations
The present study had limitations. This was a retrospec-
tive, single-center, observational cohort study. Underesti-
mations of late events (reoperations, major bleeding and
strokes) were possible. Paradoxically, our method has the
potential to create a sampling bias that overestimates the
long-term outcomes, because patients without events could
be less well represented in our follow-up data. Also, some of
the prostheses used in the present study are no longer
commercially available, which could have altered the
outcome. Despite our efforts to produce an evenly matched
subset of comparable patients using a comprehensive
step-wise logistic regression propensity score analysis, the
potential always exists for confounders that are unmeasured
and unknown. Also, we could not exclude the possibility
that patients who were lost to follow-up had experienced
subsequent events that were not captured in our study.
However, although our study was limited by its retrospec-
tive nature, we attempted to minimize the bias by usingThe Journal of Thoracic and Capropensity matched analysis. This provided the balance of
the 2 comparative groups with weighted effects of the
variables and minimized the bias on assigning the valve
types. The present study is 1 of the largest studies using
propensity matched analysis in this specific age group.
CONCLUSIONS
Despite the recent trend of placing bioprosthetic valves in
younger patients<65 years old, the present study has shown
that patients who received a bioprosthetic valve have
shorter survival than patients who received a mechanical
valve for MVR. More reoperations occurred in the MVRb
group, and the bleeding risk, which is considered a risk of
mechanical valve implantation, was similar between the
2 groups. This might explain the poor outcome in this
population. It is uncertain how the new bioprosthetic valve
with longer durability and VIV TMVR will play role in the
future. However, the results of the present study, 1 of the
largest retrospective series on this subject with propensity
matched analysis, have reaffirmed the recommendation to
use the mechanical valve for MVR in those<65 years old.
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